Two proven compounds, a proven interaction, and an unmeasured result. Where the evidence stops is the most useful thing to know about this blend.
The most popular growth hormone stack in the field has never been tested as a stack.
That sentence is not an attack on it. The two halves have each been through human trials, and the reason for combining them rests on a genuine human finding. But it changes what kind of claim you are making when you say the blend works, and it is worth being precise about that before anything else.
Two separate signals drive growth hormone release, through two receptors that do not overlap.
CJC-1295 copies GHRH, the hypothalamic signal that tells pituitary somatotroph cells to build growth hormone and put it out. Ipamorelin copies ghrelin, the gut hormone that hits the GHS-R1a receptor instead. Ghrelin does two jobs at once: it dumps what is already stored, and it shuts off somatostatin, the brake on the whole system.
Fire one and you get a response. Fire both and you get more than the two added up.
The reason is worth spelling out. "Synergy" usually gets left as a word rather than a mechanism. It has three parts:
More cells respond. GHRH raises the number of somatotroph cells releasing at all.
Each cell releases more. The ghrelin side raises the amount coming out of each one.
The brake comes off. Ipamorelin suppresses somatostatin, so the GHRH signal is not fighting an inhibitor while it works.
More workers, a bigger load each, and the door unlocked on the way out. Three different levers. That is why pulling all three does not simply add up.
Here is where the line sits.
The synergy itself is shown in humans. Bowers and colleagues, 1990, in 18 normal men. Low doses of a ghrelin-pathway compound plus GHRH raised growth hormone synergistically, which confirms the two run on separate routes. That is the mechanistic foundation, and it is real human data, replicated since.
Each compound's own effect is demonstrated in humans. The CJC-1295 trials (in the DAC version — not the one in the blend) showed growth hormone up two- to tenfold and IGF-1 up one and a half to threefold. The ipamorelin dose-escalation work in 40 healthy men put its half-life near two hours, with peak release around 40 minutes. Raun's 1998 study showed it raises growth hormone without dragging cortisol, ACTH or prolactin along, even at 200 times the working dose.
What has never been measured is the outcome. No published randomised trial has tracked body composition, strength, recovery or performance from this combination in healthy, resistance-trained adults. Not one.
So the chain runs: proven pathways, then proven synergy at the hormone level, then inference the rest of the way. Fat loss, recovery and connective tissue are supported by clinical observation and user reports. That is still inference.
That is a much better position than most compounds in this field occupy. It is still not the same as a trial showing the outcome you actually care about.
Two swaps happen quietly when this blend is discussed, and both are worth catching.
The CJC-1295 human data comes from the DAC version, which stays active for the better part of a week. The blend contains the no-DAC version, which clears in minutes. The receptor and the pituitary response are the same; the exposure profile is not remotely the same.
And Bowers' synergy work used a ghrelin-pathway compound of that era, not ipamorelin specifically. The pathway independence carries over cleanly. The exact numbers do not.
Neither substitution is unreasonable. Both are the kind of thing worth knowing you are doing.
A point that gets lost: growth hormone does not build muscle, burn fat or repair tissue by itself.
It travels to the liver, and the liver turns it into IGF-1. IGF-1 is what does the work — protein synthesis, fat mobilisation, repair, collagen. Growth hormone is the message; IGF-1 is the labour.
And the body has an awkward split to manage here. Growth hormone comes out best when you are fasted, with insulin low and ghrelin high. The liver converts it best with insulin present, meaning fed. Two opposite conditions.
The body handles it by separating them in time. The big pulse comes during fasted sleep. The hormone circulates for a few hours. Conversion picks up when the next meal raises insulin. Any timing rule that ignores half of that sequence is answering half the question.
Because both compounds work through signals, the pituitary still sets the size of the response and somatostatin still applies the brake. The regulation stays intact. That is the structural argument for secretagogues over injected growth hormone, which overrides the system and eventually suppresses your own production.
It also produces a hard rule. Do not run this blend alongside exogenous growth hormone or IGF-1. Injected growth hormone raises IGF-1, IGF-1 raises somatostatin, and somatostatin blocks the pituitary from answering either signal. Published work found the GHRH pathway heavily blocked, and the ghrelin pathway blunted too, after a single dose of injected growth hormone.
You would be buying two compounds to shout at a pituitary that has been told to stop listening. These are tools for different jobs, not tools that combine.
Sleep is the first thing almost everyone notices, usually inside two weeks. GHRH deepens slow-wave sleep directly, and that is the phase carrying the largest natural pulse.
Less often mentioned: for some people the first three or four weeks bring disrupted sleep instead. Two or three wakings a night, settling somewhere around week four to six. It is easy to read that as the compound failing, and to stop there. Knowing it is a normal adjustment is worth more than most of the fine-tuning advice attached to this stack.
Vivid dreams travel with it, for the same reason.
The timeline runs long. Recovery improvements in the first month. Body composition around weeks eight to twelve. Connective tissue, skin and joints at three to six months.
Fat loss here is slower than a diet or a GLP-1 agonist gives you. It amplifies what your training and diet already do. It does not stand in for them.
The honest framing: this class does not replace testosterone for building muscle. Anyone expecting steroid-scale growth will be disappointed. And most people who decide the blend did nothing had stopped before the slow benefits arrived. What it offers is recovery, sleep, gradual body composition change and connective tissue health, over months.
Receptor desensitisation is real, and it happens on two timescales that are nowhere near each other.
The fast kind sets in within minutes of a dose and clears in about an hour — perifused rat pituitary cells recovered full sensitivity after 60 minutes. Two days off is irrelevant to something that resolves on its own before dinner.
The slow kind takes roughly 16 weeks of continuous use to develop and about four weeks off to reverse, going by the hexarelin study in 12 elderly subjects. Two days off is nowhere near enough to touch it.
So the schedule sits in the gap between the two, and addresses neither. Meanwhile the tesamorelin trials that won FDA approval dosed daily for 26 weeks. The MK-677 trials dosed daily for two years. Growth hormone and IGF-1 stayed up throughout.
One fair concession the source makes, and I will keep it: dosing five days a week is a perfectly reasonable way to make a vial last longer. It saves roughly 30% on product. Just call it a budget decision, because that is what it is, and not a receptor one.
The common ones are mild and mostly settle within two weeks. Injection site redness, mild water retention, brief flushing, passing tingling in the fingers, vivid dreams, and some lightheadedness at higher doses. Headache, slightly increased hunger, fatigue while adjusting and small blood sugar swings show up less often.
The useful part is knowing where the ceiling is. Persistent numbness or tingling in the hands, carpal tunnel symptoms, joint swelling or facial puffiness mean the dose is too high. These are not side effects to push through. They are the system telling you the growth hormone elevation has passed what it can handle cleanly, and the answer is less, not more.
Active cancer or tumours is the firm exclusion. Growth hormone and IGF-1 can speed tumour growth, and any cancer history needs an oncologist's clearance first. Also excluded: diabetic retinopathy, uncontrolled diabetes, and pregnancy or breastfeeding.
Take care with type 2 diabetes or prediabetes, past carpal tunnel trouble, heart disease, raised blood pressure, and kidney or liver disease.
Glucocorticoids such as prednisone blunt the growth hormone response. Insulin and oral diabetes medications may need adjusting, with a physician.
For monitoring, IGF-1 is the marker that matters — it tells you both whether the pathway actually moved and whether it has gone too far. Fasting glucose and HbA1c cover the insulin sensitivity question. Sleep tells you something is happening; only blood work tells you what.
This article explains published research and the rules around it. It carries no dose, no protocol, and no claim that any compound treats, cures or prevents a condition in anyone. Where the evidence is thin we say so. See our editorial standards.
Research-grade material, sold for laboratory research use. We link to a single supplier rather than a list, so you know exactly where the recommendation goes. Check the certificate of analysis against what a COA can and cannot show before you buy anything.
Commercial link. Nothing on this page is a dose, a protocol, or a claim that this compound treats or prevents any condition.
KLOW is GLOW plus 10 mg of KPV — that part is simple. The more useful fact is that both are, by mass, mostly copper peptide, and that is the ingredient whose injected form has no human trials.
An open study found sleep normalised in six of seven patients. The controlled study by the same investigator found weak effects and said so. The difference between them is a placebo arm.
It does not raise dopamine — it magnifies what other things do to it. That one property explains why caffeine feels stronger on it, and why MAO inhibitors are a hard contraindication.
